Article

FDA grants priority review to possible treatment for DR

The Food and Drug Administration (FDA) granted priority reviewstatus to Eli Lilly & Co.'s ruboxistaurin mesylate (proposedbrand name Arxxant), a possible treatment for diabetic retinopathy(DR).

The FDA granted priority review status to Eli Lilly & Co.'s ruboxistaurin mesylate (proposed brand name Arxxant), a possible treatment for diabetic retinopathy (DR).

In a phase III clinical trial, ruboxistaurin significantly reduced the occurrence of sustained moderate visual loss in patients being treated for moderate-to-very-severe DR. The 3-year trial involved 685 patients.

More than 2,000 patients have been treated with ruboxistaurin in clinical trials. Some patients have taken the drug for up to 4 years. No significant safety issues have been identified in any of the clinical trials.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI Myopia Workshop: Michael X. Repka, MD, MBA, on building consensus and future directions
(Image credit: Ophthalmology Times) Introducing iOpeners: Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
© 2025 MJH Life Sciences

All rights reserved.